Legend Biotech Corporation
LEGN
Kedudukan dalam Saham
#4479
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Harga Saham
$18.60
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$3.44B
Perubahan (1 hari)
-6.06%
Perubahan (1 tahun)
-41.80%
Negara
US
Perdagangan Legend Biotech Corporation (LEGN)
Kategori
Healthcare
Margin Operasi untuk Legend Biotech Corporation (LEGN)
Margin Operasi pada October 2026 TTM: -4.42%
Menurut laporan kewangan dan harga saham terkini Legend Biotech Corporation, margin operasi semasa (TTM) ialah -4.42%. Pada akhir 2023, margin operasi syarikat ialah -154.13%.
Sejarah Margin Operasi untuk Legend Biotech Corporation dari 2017 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Ubah |
|---|---|---|
| 2026 (TTM) | -4.42% | -90.86% |
| 2024 | -48.35% | -68.63% |
| 2023 | -154.13% | -60.44% |
| 2022 | -389.58% | -11.00% |
| 2021 | -437.71% | 5.71% |
| 2020 | -414.06% | 81.18% |
| 2019 | -228.54% | 7,225.00% |
| 2018 | -3.12% | -105.34% |
| 2017 | 58.41% | 0.00% |
Margin Operasi untuk syarikat serupa atau pesaing
| Syarikat | Margin Operasi | Perbezaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -108.73% |
US
|
|
| -149.01% | -66.29% |
US
|
|
| 25.57% | -105.79% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -106.52% |
NL
|
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.